December 21, 2016
Kiadis Pharma provides update on Phase II trial with cancer drug
Kiadis Pharma has announced an update on the second dose Phase II trial with ATIR101 (CR-AIR-008 ).
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
December 21, 2016
Galapagos’s study of cystic fibrosis drug shows good results
Galapagos has reported topline results from its Saphira 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.
December 21, 2016
Takeda makes EUR10 million equity investment in TiGenix
Belgian based biopharmaceutical company TiGenix has exercised the option granted by Takeda under the licensing agreement to make a EUR10…
December 21, 2016
FDA accepts Vernalis and Tris Pharma’s NDA for cough drug
U.S. Food and Drug Administration (“FDA”) has accepted Vernalis and Tris Pharma’s CCP-08 New Drug Application (“NDA”) for full review.…
December 21, 2016
Bayer and Leica Biosystems unite to fight cancer
Bayer has entered into an agreement with Leica Biosystems to collaborate on the development of companion diagnostic tests based on…
December 21, 2016
Premaitha buys Taiwanian bioinformatic company
Premaitha has announced the conditional acquisition of the entire issued share capital of Yourgene.
December 20, 2016
BMS gets exclusive rights to study PsiOxus’s cancer drug
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
December 20, 2016
Pharnext enrolls patients for Charcot-Marie-Tooth disease study in Europe, US, and Canada.
A French biopharmaceutical company Pharnext set to produce treatments to tackle neuropathy diseases, has completed patient enrollment for its international…
December 20, 2016
Novartis buys private US-based pharma company, exapnds its ophtalmology pipeline
Novarits is expanding its ophthalmology pipeline as it secured the ownership of a US-based private company focused on treating long-sightedness.
December 20, 2016
GSKs two-drug HIV treatment regimen could become one tablet
Two phase III studies of two-drug HIV treatment regimen conducted by GSK’s HIV specialist ViiV Healthcare, Pfizer and Shinogi Limited,…